Binding, Casper Olesen, Jonas Bjerring Lee, Christina Ji-Young Lip, Gregory Y H Sindet-Pedersen, Caroline Gislason, Gunnar Bonde, Anders Nissen
Published in
European heart journal. Cardiovascular pharmacotherapy
The aim of this study was to evaluate the risk of discontinuing treatment with direct oral anticoagulants (DOACs) among patients with atrial fibrillation (AF) according to cohabitation status and gender. Using the Danish national registers, we identified 32 364 patients with AF aged 40-90 years undergoing treatment with DOACs. The study period was ...
Ding, Wern Yew Boriani, Giuseppe Marin, Francisco Blomström-Lundqvist, Carina Potpara, Tatjana S Fauchier, Laurent Lip, Gregory Y H
Published in
European heart journal. Cardiovascular pharmacotherapy
The safety of digoxin therapy in atrial fibrillation (AF) remains ill-defined. We aimed to evaluate the effects of digoxin over beta-blocker therapy in AF. Patients with AF who were treated with either digoxin or a beta blocker from the ESC-EHRA EORP AF (European Society of Cardiology-European Heart Rhythm Association EURObservational Research Prog...
Capodanno, Davide Angiolillo, Dominick J
Published in
European heart journal. Cardiovascular pharmacotherapy
Stroke is frequently a disabling and even life-threatening condition that has an ischaemic cause in most cases. Transient ischaemic attack (TIA) is a lower risk condition that still exposes to the risk of future major cardiovascular events. The causes of stroke can be classified as cardioembolic disease, large vessel disease, small vessel disease, ...
Hu, Wei-Syun Lin, Cheng-Li
Published in
European heart journal. Cardiovascular pharmacotherapy
We conducted this study to explore the associations of weekend and weekday admission with the clinical events among heart failure (HF) patients with and without comorbid atrial fibrillation (AF). In this study, we recruited 57 919 HF patients without AF hospitalized on weekends and 57 919 HF patients without AF hospitalized on weekdays. There were ...
Thangjui, Sittinun Kewcharoen, Jakrin Yodsuwan, Ratdanai Trongtorsak, Angkawipa Thyagaturu, Harshith Shrestha, Bishesh Winans, Amanda R M Bischof, Edward
Published in
European heart journal. Cardiovascular pharmacotherapy
We conducted a systematic review and meta-analysis on three outcomes. We assessed the efficacy and safety of direct oral anticoagulants (DOAC) compared to vitamin K antagonists (VKA) in morbidly obese patients with atrial fibrillation (AF). We compared the efficacy and safety of DOAC in obese patients and non-obese patients with AF. Finally, we upd...
Vamos, Mate Oldgren, Jonas Nam, Gi-Byoung Lip, Gregory Y H Calkins, Hugh Zhu, Jun Ueng, Kwo-Chang Ludwigs, Ulf Wieloch, Mattias Stewart, John
...
Published in
European heart journal. Cardiovascular pharmacotherapy
Use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is challenging owing to issues with renal clearance, drug accumulation, and increased proarrhythmic risks. Because CKD is a common comorbidity in patients with atrial fibrillation/atrial flutter (AF/AFL), it is important to establish the efficacy and safety of AAD trea...
Chen, Shaojie Pürerfellner, Helmut Meyer, Christian Sommer, Philipp Kiuchi, Márcio Galindo Martinek, Martin Futyma, Piotr Zanchi, Simone Zhu, Lin Schratter, Alexandra
...
Published in
European heart journal. Cardiovascular pharmacotherapy
Anticoagulation for atrial fibrillation patients with liver disease represents a clinical dilemma. We sought to evaluate the efficacy/safety of different anticoagulation, i.e. vitamin K antagonist (VKA) and non-VKA oral anticoagulants (NOACs) in such patient group. This was a pooled-analysis enrolling up-to-date clinical data. Two subsets: subset A...
Tamargo, Juan Kjeldsen, Keld Per Delpón, Eva Semb, Anne Grete Cerbai, Elisabetta Dobrev, Dobromir Savarese, Gianluigi Sulzgruber, Patrick Rosano, Giuseppe Borghi, Claudio
...
Published in
European heart journal. Cardiovascular pharmacotherapy
Population ageing has resulted in an increasing number of older people living with chronic diseases (multimorbidity) requiring five or more medications daily (polypharmacy). Ageing produces important changes in the cardiovascular system and represents the most potent single cardiovascular risk factor. Cardiovascular diseases (CVDs) constitute the g...
Cirne, Filipe Aghel, Nazanin Petropoulos, Jo-Anne Klotz, Laurence Lenihan, Daniel J Saad, Fred Pinthus, Jehonathan Leong, Darryl P
Published in
European heart journal. Cardiovascular pharmacotherapy
The aim of this study was to determine whether gonadotropin-releasing hormone (GnRH) antagonists (an emerging class of drugs to suppress testosterone synthesis in the treatment of prostate cancer) cause less adverse cardiovascular events than the more commonly use GnRH agonists. We conducted a systematic review to identify all randomized, controlle...
Aguilar-Gallardo, Jose S Correa, Ashish Contreras, Johanna P
Published in
European heart journal. Cardiovascular pharmacotherapy
The heart and the kidneys are closely interconnected, and disease in one organ system can lead to disease in the other. This interdependence is illustrated in heart failure with reduced ejection fraction (HFrEF), where worsening heart failure (HF) can lead to renal dysfunction and vice versa. Further complicating this situation is the fact that dru...
